A recent experimental study found that EZH2 inhibitor can induce simultaneous upregulation of GPX4 and TfR-1, leading to resistance of DLBCL cells to EZH2 inhibitor. This evidence concerns the gene GPX4 and diffuse large B-cell lymphoma.